An Open-Label Study to Evaluate the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Cenicriviroc and Its Metabolites Following Single Dose Administration
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Cenicriviroc (Primary)
- Indications Liver cirrhosis; Liver disorders; Liver failure
- Focus Pharmacokinetics
- Sponsors Allergan
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 28 Dec 2017 New trial record